for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dechra Pharmaceuticals plc

DPH.L

Latest Trade

2,780.00GBp

Change

30.00(+1.09%)

Volume

325,257

Today's Range

2,724.00

 - 

2,792.00

52 Week Range

1,992.00

 - 

3,080.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
2,750.00
Open
2,724.00
Volume
325,257
3M AVG Volume
5.61
Today's High
2,792.00
Today's Low
2,724.00
52 Week High
3,080.00
52 Week Low
1,992.00
Shares Out (MIL)
102.81
Market Cap (MIL)
2,827.30
Forward P/E
28.11
Dividend (Yield %)
--

Next Event

Half Year 2020 Dechra Pharmaceuticals PLC Earnings Release

Latest Developments

More

Dechra Pharma Names Paul Sandland As Permanent CFO

Dechra Pharmaceuticals Says Confident About FY Prospects

Kane Biotech And Dechra Veterinary Products Expand Exclusive License And Distribution Agreement To Include South America

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.

Industry

Biotechnology & Drugs

Contact Info

24 Cheshire Business Park

Cheshire Avenue

+44.1606.814730

http://www.dechra.com/

Executive Leadership

Tony Rice

Non-Executive Chairman of the Board

Ian David Page

Chief Executive Officer, Executive Director

Paul Sandland

Chief Financial Officer, Executive Director

Mike Eldred

President, North America

Anthony Gerard Griffin

Managing Director - Dechra Veterinary Products Europe, Executive Director

Key Stats

2.22 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

0.4K

2018

0.4K

2019

0.5K

2020(E)

0.5K
EPS (GBp)

2017

64.330

2018

76.450

2019

90.010

2020(E)

97.826
Price To Earnings (TTM)
91.46
Price To Sales (TTM)
5.87
Price To Book (MRQ)
5.54
Price To Cash Flow (TTM)
24.06
Total Debt To Equity (MRQ)
60.52
LT Debt To Equity (MRQ)
60.28
Return on Investment (TTM)
3.33
Return on Equity (TTM)
2.99

Latest News

Latest News

Dechra ramps up contingency plan for a potential hard Brexit

Veterinary drugs producer Dechra Pharmaceuticals Plc <DPH.L> said on Monday it changed the ownership of all UK marketing authorisations to a new unit in the Netherlands, as it prepares for a potential hard Brexit.

Dechra ramps up contingency plan for a potential hard Brexit

British veterinary firm Dechra Pharmaceuticals said on Monday it changed the ownership of all UK marketing authorisations to a new unit in the Netherlands, as it prepares for a potential hard Brexit.

UPDATE 1-UK's Dechra Pharma says to implement hard Brexit plan

Veterinary drugs producer Dechra Pharmaceuticals said on Monday it was moving ahead with plans for a hard Brexit, stressing the financial impact should be "immaterial" but spooking investors worried about revenue and operations after next year's split.

UK's Dechra Pharma says to implement hard Brexit plan

British veterinary firm Dechra Pharmaceuticals said on Monday it would implement a plan to navigate a hard Brexit.

BRIEF-Dechra Pharmaceuticals Says HY Revenue Up 11 Pct

* SAYS REPORTED GROUP REVENUE FOR SIX MONTHS ENDED 31 DECEMBER 2017 INCREASED BY 11.2% AT CONSTANT EXCHANGE RATE

BRIEF-Dechra Pharmaceuticals ‍Raises 105 Mln Stg Via Placing

* ANNOUNCES SUCCESSFUL COMPLETION OF PLACING ANNOUNCED EARLIER TODAY

UK's Dechra to buy Dutch firms AST Farma, Le Vet for $422 million

Veterinary firm Dechra Pharmaceuticals Plc said it would buy the Netherlands-based AST Farma and Le Vet for a total of 340 million euros ($422.1 million) in a cash-and-share deal to boost its presence in Europe.

UK's Dechra to buy Dutch firms AST Farma, Le Vet for 340 mln euros

Veterinary firm Dechra Pharmaceuticals Plc said it would buy the Netherlands-based AST Farma and Europe-focused Le Vet for 340 million euros ($422.1 million) in a cash and share deal.

BRIEF-Dechra Pharmaceuticals to acquire Ast Farma and Le Vet

* BOARD OF DECHRA, INTERNATIONAL VETERINARY PHARMACEUTICAL BUSINESS, IS PLEASED TO ANNOUNCE THAT IT HAS ENTERED INTO A CONDITIONAL ACQUISITION AGREEMENT TO ACQUIRE AST FARMA AND LE VET FOR A TOTAL CONSIDERATION OF EUR 340.0 MILLION ON A DEBT-FREE AND CASH-FREE BASIS

BRIEF-Dechra Pharmaceuticals ‍Q1 performance in line with management expectations

* DECHRA PHARMACEUTICALS - PERFORMANCE IN Q1 OF FINANCIAL YEAR WAS IN LINE WITH MANAGEMENT EXPECTATIONS, WITH CONTINUED GROWTH ACROSS ALL OF ITS MARKETS Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

BRIEF-Dechra says trading in line with management expectations

* Trading in full year was strong and in line with management expectations

BRIEF-Kane Biotech says entered into license and distribution agreement with Dechra Veterinary Products

* Kane biotech inc- terms of agreement are confidential between parties and further financial details are not disclosed

BRIEF-Dechra Pharmaceuticals says half-year revenue up at 172.6 mln stg

* Half-Yearly financial report 2017 for six months ended 31 december 2016

BRIEF-Dechra Pharma expresses confidence about its FY expectations

* Issues following unaudited trading update covering half year reporting period from 1 July to 31 December 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up